SCHEMBL31408430

SCHEMBL31408430

COc1cnc(-c2cc3[nH]c(CNC(=O)N4CCC4)cc3cc2Cl)cn1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MLLT1 Q03111 1/20 0.35
▸ KIT P10721 5/20 0.34
▸ P2RY12 Q9H244 2/20 0.33
▸ ALK Q9UM73 1/20 0.33
▸ PTGES O14684 1/20 0.33
▸ PDK1 Q15118 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ EPHX2 P34913 1/20 0.32
▸ CYP2J2 P51589 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31408279 0.93 SMN1; SMN2 (0.36) MAPK1SMN1; SMN2MLLT1KITP2RY12
SCHEMBL31408356 0.92 POLB (0.39) MAPK1SMN1; SMN2MLLT1PDK1HPGD
SCHEMBL31408537 0.90 SMN1; SMN2 (0.36) MAPK1SMN1; SMN2MLLT1KITALK
SCHEMBL31408514 0.90 SMN1; SMN2 (0.36) MAPK1SMN1; SMN2MLLT1KITPTGES
SCHEMBL31408376 0.89 JAK2 (0.40) ALKMEN1KMT2A
SCHEMBL31408237 0.88 LRRK2 (0.35) MAPK1SMN1; SMN2CYP2C9CYP2C19EPHX2
SCHEMBL31408429 0.88 LRRK2 (0.35) MAPK1SMN1; SMN2CYP2C9CYP2C19EPHX2
SCHEMBL31408327 0.88 LRRK2 (0.35) MAPK1SMN1; SMN2CYP2C9CYP2C19EPHX2
SCHEMBL31408404 0.88 LRRK2 (0.36) MAPK1SMN1; SMN2MLLT1ALKPTGES
SCHEMBL31408457 0.86 SMN1; SMN2 (0.42) MAPK1SMN1; SMN2PTGESMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049604-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
Send feedback